| Dr Francois Marcotte, MD | |
|
13400 E Shea Blvd, Scottsdale, AZ 85259-5452 | |
| (480) 301-4469 | |
| (480) 301-8018 |
| Full Name | Dr Francois Marcotte |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 41 Years |
| Location | 13400 E Shea Blvd, Scottsdale, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134650633 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 53327 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mayo Clinic Hospital | Phoenix, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mayo Clinic - Arizona | 7012829930 | 1395 |
News Archive
Nowadays, COVID-19 has spread around the world, threatening billions of people as healthcare services struggle to cope. World Health Organization has now officially characterized it as a pandemic, calling for immediate and wise reactions.
HUYA Bioscience International, a leader in accelerating the global development of China's pharmaceutical innovations, today announced a strategic partnership with the Changzhou Center for Biotech Development (CZCBD).
Alphatec Holdings, Inc., the parent company of Alphatec Spine, Inc., a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, with a focus on treating conditions related to the aging spine, announced that is has priced an underwritten public offering of 16,000,000 shares of common stock, consisting of 8,000,000 shares to be sold by the Company and 8,000,000 shares to be sold by a selling shareholder, HealthpointCapital Partners, L.P., at a price to the public of $5.00 per share.
Monroe Carell Jr. Children's Hospital at Vanderbilt has launched a study to determine the impact of a predictive model for identifying pediatric patients at risk for developing blood clots or venous thromboembolisms (VTEs).
CHX Technologies Inc., a private Canadian pharmaceutical company that is developing new treatments for the prevention of dental diseases, today announced successful results in its final controlled pivotal trial of Prevora, its proprietary antibacterial tooth coating for the prevention of cavities. The trial surpassed objectives set by the Food and Drug Administration (FDA) protocol, clearing the way for CHX to start the process of seeking FDA approval for use in the United States.
› Verified 7 days ago
| Entity Name | Mayo Clinic Arizona |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558332494 PECOS PAC ID: 7012829930 Enrollment ID: O20031105000782 |
News Archive
Nowadays, COVID-19 has spread around the world, threatening billions of people as healthcare services struggle to cope. World Health Organization has now officially characterized it as a pandemic, calling for immediate and wise reactions.
HUYA Bioscience International, a leader in accelerating the global development of China's pharmaceutical innovations, today announced a strategic partnership with the Changzhou Center for Biotech Development (CZCBD).
Alphatec Holdings, Inc., the parent company of Alphatec Spine, Inc., a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, with a focus on treating conditions related to the aging spine, announced that is has priced an underwritten public offering of 16,000,000 shares of common stock, consisting of 8,000,000 shares to be sold by the Company and 8,000,000 shares to be sold by a selling shareholder, HealthpointCapital Partners, L.P., at a price to the public of $5.00 per share.
Monroe Carell Jr. Children's Hospital at Vanderbilt has launched a study to determine the impact of a predictive model for identifying pediatric patients at risk for developing blood clots or venous thromboembolisms (VTEs).
CHX Technologies Inc., a private Canadian pharmaceutical company that is developing new treatments for the prevention of dental diseases, today announced successful results in its final controlled pivotal trial of Prevora, its proprietary antibacterial tooth coating for the prevention of cavities. The trial surpassed objectives set by the Food and Drug Administration (FDA) protocol, clearing the way for CHX to start the process of seeking FDA approval for use in the United States.
› Verified 7 days ago
| Entity Name | District Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336472448 PECOS PAC ID: 7315086691 Enrollment ID: O20091125000583 |
News Archive
Nowadays, COVID-19 has spread around the world, threatening billions of people as healthcare services struggle to cope. World Health Organization has now officially characterized it as a pandemic, calling for immediate and wise reactions.
HUYA Bioscience International, a leader in accelerating the global development of China's pharmaceutical innovations, today announced a strategic partnership with the Changzhou Center for Biotech Development (CZCBD).
Alphatec Holdings, Inc., the parent company of Alphatec Spine, Inc., a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, with a focus on treating conditions related to the aging spine, announced that is has priced an underwritten public offering of 16,000,000 shares of common stock, consisting of 8,000,000 shares to be sold by the Company and 8,000,000 shares to be sold by a selling shareholder, HealthpointCapital Partners, L.P., at a price to the public of $5.00 per share.
Monroe Carell Jr. Children's Hospital at Vanderbilt has launched a study to determine the impact of a predictive model for identifying pediatric patients at risk for developing blood clots or venous thromboembolisms (VTEs).
CHX Technologies Inc., a private Canadian pharmaceutical company that is developing new treatments for the prevention of dental diseases, today announced successful results in its final controlled pivotal trial of Prevora, its proprietary antibacterial tooth coating for the prevention of cavities. The trial surpassed objectives set by the Food and Drug Administration (FDA) protocol, clearing the way for CHX to start the process of seeking FDA approval for use in the United States.
› Verified 7 days ago
| Entity Name | Mayo Clinic Jacksonville |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790772317 PECOS PAC ID: 5698689297 Enrollment ID: O20181009000548 |
News Archive
Nowadays, COVID-19 has spread around the world, threatening billions of people as healthcare services struggle to cope. World Health Organization has now officially characterized it as a pandemic, calling for immediate and wise reactions.
HUYA Bioscience International, a leader in accelerating the global development of China's pharmaceutical innovations, today announced a strategic partnership with the Changzhou Center for Biotech Development (CZCBD).
Alphatec Holdings, Inc., the parent company of Alphatec Spine, Inc., a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, with a focus on treating conditions related to the aging spine, announced that is has priced an underwritten public offering of 16,000,000 shares of common stock, consisting of 8,000,000 shares to be sold by the Company and 8,000,000 shares to be sold by a selling shareholder, HealthpointCapital Partners, L.P., at a price to the public of $5.00 per share.
Monroe Carell Jr. Children's Hospital at Vanderbilt has launched a study to determine the impact of a predictive model for identifying pediatric patients at risk for developing blood clots or venous thromboembolisms (VTEs).
CHX Technologies Inc., a private Canadian pharmaceutical company that is developing new treatments for the prevention of dental diseases, today announced successful results in its final controlled pivotal trial of Prevora, its proprietary antibacterial tooth coating for the prevention of cavities. The trial surpassed objectives set by the Food and Drug Administration (FDA) protocol, clearing the way for CHX to start the process of seeking FDA approval for use in the United States.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Francois Marcotte, MD 13400 E Shea Blvd, Scottsdale, AZ 85259-5452 Ph: (480) 301-4469 | Dr Francois Marcotte, MD 13400 E Shea Blvd, Scottsdale, AZ 85259-5452 Ph: (480) 301-4469 |
News Archive
Nowadays, COVID-19 has spread around the world, threatening billions of people as healthcare services struggle to cope. World Health Organization has now officially characterized it as a pandemic, calling for immediate and wise reactions.
HUYA Bioscience International, a leader in accelerating the global development of China's pharmaceutical innovations, today announced a strategic partnership with the Changzhou Center for Biotech Development (CZCBD).
Alphatec Holdings, Inc., the parent company of Alphatec Spine, Inc., a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, with a focus on treating conditions related to the aging spine, announced that is has priced an underwritten public offering of 16,000,000 shares of common stock, consisting of 8,000,000 shares to be sold by the Company and 8,000,000 shares to be sold by a selling shareholder, HealthpointCapital Partners, L.P., at a price to the public of $5.00 per share.
Monroe Carell Jr. Children's Hospital at Vanderbilt has launched a study to determine the impact of a predictive model for identifying pediatric patients at risk for developing blood clots or venous thromboembolisms (VTEs).
CHX Technologies Inc., a private Canadian pharmaceutical company that is developing new treatments for the prevention of dental diseases, today announced successful results in its final controlled pivotal trial of Prevora, its proprietary antibacterial tooth coating for the prevention of cavities. The trial surpassed objectives set by the Food and Drug Administration (FDA) protocol, clearing the way for CHX to start the process of seeking FDA approval for use in the United States.
› Verified 7 days ago
Russell S Ruzich, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 13400 E Shea Blvd, Scottsdale, AZ 85259 Phone: 480-301-8000 | |
Dr. Paul Joseph Schenk, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 11230 E Beck Ln, Scottsdale, AZ 85255 Phone: 480-502-9457 | |
Dr. Musab Sultan Hommos, M.B., B.S. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 13400 E Shea Blvd, Scottsdale, AZ 85259 Phone: 480-301-8000 | |
Soyoung Park, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 10460 N 92nd St Ste 300, Scottsdale, AZ 85258 Phone: 480-323-1573 Fax: 480-323-1375 | |
Dr. Michael Edward Killian, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: Mayo Clinic 13400 E Shea Blvd, Scottsdale, AZ 85259 Phone: 085-120-6856 | |
Hesham Mubarak Ibrahim Moh Abdalla, M.B.B.S. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 13400 E Shea Blvd, Scottsdale, AZ 85259 Phone: 480-301-8000 | |
Kianoush Cheybani, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 9590 E Ironwood Square Dr, Ste 125, Scottsdale, AZ 85258 Phone: 480-455-3000 Fax: 866-819-6115 |